Profil
David S.
Arrington worked as VP-Investor Relations & Corporate Communications at Achaogen, Inc. from 2017 to 2018.
He also worked as VP-Investor Relations & Corporate Affairs at Coherus BioSciences, Inc. and as VP-Investor Relations & Corporate Communications at Freeline Therapeutics Holdings Plc.
Arrington received his undergraduate degree from Washington State University.
Anciens postes connus de David S. Arrington
| Sociétés | Poste | Fin |
|---|---|---|
| ACHAOGEN | Investor Relations Contact | 01/04/2018 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Investor Relations Contact | - |
| COHERUS BIOSCIENCES, INC. | Investor Relations Contact | - |
Formation de David S. Arrington
| Washington State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
